Metabolic & Cardiometabolic
lipoprotein(a) causes cardiovascular disease
In plain terms: Is high Lp(a) an actual cause of heart disease, and can new drugs lower it?
Genetics (Mendelian randomization) and large epidemiology show Lp(a) is causally atherogenic — likely more potent per particle than LDL — and siRNA/antisense/oral agents now cut it up to ~80-99%, though cardiovascular-outcome trials are still pending.
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
How the studies fall
What the evidence shows
<!-- vault-context --> Norwitz **affirms** this claim. Consensus below reflects independent literature only.
The evidence (12)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Lee 2026 · JACC Adv | observational | supports | high | Mendelian randomization showed Lp(a) exerts a causal effect on coronary artery disease independent of LDL-C. |
| Hsu 2026 · Circ J | observational | supports | moderate | Combined observational and Mendelian randomization analyses supported a causal, largely linear association between Lp(a) and atherosclerotic cardiovascular disease. |
| Clarke 2009 · N Engl J Med | observational | supports | high | PROCARDIS: LPA SNPs (rs10455872, rs3798220) strongly and causally associated with coronary disease via raised Lp(a). |
| Bjornson 2024 · J Am Coll Cardiol | observational | supports | high | ApoB-based genetic (UK Biobank): per-particle, Lp(a) markedly MORE atherogenic than LDL — supports the more-atherogenic-per-particle claim. |
| Burgess 2018 · JAMA Cardiol | observational | supports | high | Genetic analysis: ~100 mg/dL Lp(a) lowering needed for CHD benefit comparable to ~40 mg/dL LDL — quantifies causal Lp(a) effect. |
| Nicholls 2023 · JAMA | RCT | supports | moderate | Phase 1 oral muvalaplin: well tolerated, reduced Lp(a) up to ~65% — proof-of-concept for oral Lp(a) lowering. |
| OCEAN(a)-DOSE 2025 · Eur Heart J | RCT | supports | high | Phase 2 olpasiran siRNA: lowered Lp(a) by ~95-99% across baseline levels; surrogate endpoint only, outcome trial OCEAN(a)-Outcomes ongoing. |
| Kamstrup 2009 · JAMA | observational | supports | high | Mendelian randomization (Copenhagen): genetically elevated Lp(a) via LPA KIV-2 causally raises myocardial infarction risk. |
| Nicholls 2025 · JAMA | RCT | supports | moderate | Phase 2 oral muvalaplin: placebo-adjusted Lp(a) reductions up to ~86% over 12 wk; no outcome data yet, oral small molecule. |
| Tsimikas 2020 · N Engl J Med | RCT | supports | high | Phase 2 pelacarsen (apo(a) antisense): dose-dependent Lp(a) reduction up to ~80% in CVD patients; outcomes (Lp(a)HORIZON) pending. |
| Daghlas 2026 · J Am Heart Assoc | observational | mixed | moderate | Mendelian randomization supported a causal Lp(a) effect on large-artery/atherosclerotic stroke but not on all cerebrovascular subtypes. |
| Wu 2026 · Pharmacol Res | meta-analysis | supports | high | Network meta-analysis of 25 RCTs showed siRNA and antisense agents lower Lp(a) by 54-92%, confirming the new drugs can potently reduce Lp(a). |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.